Supply Chain Intelligence

Madrigal Pharmaceuticals, Inc. Supply Chain

MDGL supply chain intelligence for Madrigal Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

MDGL ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

9Suppliers
17Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Madrigal Pharmaceuticals, Inc. (MDGL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

30Total relationships
4Distinct source URLs
6High confidence
0.736Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Madrigal Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
F-HOFFMANN-LA-ROCHE-LTD F-HOFFMANN-LA-ROCHE-LTD 90% Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment
HOFFMANN-LA-ROCHE-INC HOFFMANN-LA-ROCHE-INC 90% Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment
GYRE Gyre Therapeutics, Inc. 72% Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product can…
IVA Inventiva S.A. 72% Reciprocal relationship from IVA graph: Reciprocal relationship from MDGL graph: hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, …
IVA Inventiva S.A. 72% hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf…
NVO Novo Nordisk A/S 72% Reciprocal relationship from NVO graph: Reciprocal relationship from MDGL graph: hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, …
NVO Novo Nordisk A/S 72% hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf…
ORANY ORANY 72% rice for supply of resmetirom is based on the volume of material subject to a purchase order. The initial term of the Evonik Agreement will expire on December 31, 2029 and will be automatically renew…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from MDGL graph: rice for supply of resmetirom is based on the volume of material subject to a purchase order. The initial term of th…

Madrigal Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
HTGC Hercules Capital, Inc. 72% Reciprocal relationship from HTGC graph: Reciprocal relationship from MDGL graph: h and development is very expensive, time-consuming and difficult to design and implement and involves uncertain outc…
HTGC Hercules Capital, Inc. 72% h and development is very expensive, time-consuming and difficult to design and implement and involves uncertain outcomes. Furthermore, the results of preclinical studies and earlier clinical trials …
IVA Inventiva S.A. 72% Reciprocal relationship from IVA graph: Reciprocal relationship from MDGL graph: hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, …
IVA Inventiva S.A. 72% hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf…
NVO Novo Nordisk A/S 72% hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf…
NVO Novo Nordisk A/S 72% Reciprocal relationship from NVO graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from NVO graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from NVO grap…
OBDC Blue Owl Capital Corporation 72% Reciprocal relationship from OBDC graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from OBDC g…
OBDC Blue Owl Capital Corporation 72% wo Phase 1 trials suggested that a single dose of ARO-PNPLA3 reduced liver fat content in homozygous carriers of the PNPLA3 I148M variant, providing proof-of-concept for ARO-PNPLA3 as a precision-med…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from MDGL graph: hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage…
ORANY ORANY 72% hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf…
VKTX Viking Therapeutics, Inc. 72% Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinica…
CO-LLC-JEFFERIES-LLC CO-LLC-JEFFERIES-LLC 62% with changes in the prime rate. The First Amendment reduced the interest rate under the Amended Loan Facility to the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.45% an…
COMPANY-LLC COMPANY-LLC 62% he year ended December 31, 2023. The increase in interest expense was primarily the result of a higher average outstanding principal balance during the period under the Loan Facility with Hercules. C…
COMPANY-LLC-EVERCORE-GROUP COMPANY-LLC-EVERCORE-GROUP 62% with changes in the prime rate. The First Amendment reduced the interest rate under the Amended Loan Facility to the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.45% an…
F-HOFFMANN-LA-ROCHE-AG F-HOFFMANN-LA-ROCHE-AG 62% wo Phase 1 trials suggested that a single dose of ARO-PNPLA3 reduced liver fat content in homozygous carriers of the PNPLA3 I148M variant, providing proof-of-concept for ARO-PNPLA3 as a precision-med…
LSI-FINANCING-LLC LSI-FINANCING-LLC 62% wo Phase 1 trials suggested that a single dose of ARO-PNPLA3 reduced liver fat content in homozygous carriers of the PNPLA3 I148M variant, providing proof-of-concept for ARO-PNPLA3 as a precision-med…
USA-LLC USA-LLC 62% y of drug product for European commercialization. Additional changes to the policies of the United States or other nations that affect the geopolitical landscape or global trade, economy or market co…

Madrigal Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
MDGL-DEBT-10916 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-05-09.
MDGL-DEBT-10915 Warrants outstanding: 4555 90% xbrl warrant detail from xbrl 2023-12-31.
MDGL-DEBT Debt stack $340.8M 90% Market cache reports total debt of $340.8M.

Madrigal Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
MDGL-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 384 tracked holders.

Madrigal Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CMPS COMPASS Pathways plc 100.00 2
PHGE BiomX Inc. 100.00 2
ORANY ORANGE 100.00 1 ['customer', 'supplier']
ALEC Alector, Inc. 100.00 2
SVRA Savara Inc. 100.00 2
KURA Kura Oncology, Inc. 100.00 2
LGND Ligand Pharmaceuticals Incorporated 100.00 2
IRON Disc Medicine, Inc. 100.00 2
ALT Altimmune, Inc. 100.00 2
GYRE Gyre Therapeutics, Inc. 100.00 1 ['supplier']
DB Deutsche Bank Aktiengesellschaft 100.00 2
ENGN enGene Therapeutics Inc. 100.00 2
IVA Inventiva S.A. 100.00 1 ['customer', 'supplier']
TGTX TG Therapeutics, Inc. 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
BBIO BridgeBio Pharma, Inc. 100.00 2
NVO Novo Nordisk A/S 100.00 1 ['customer', 'supplier']
SGHT Sight Sciences, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Madrigal Pharmaceuticals, Inc..

Unlock full MDGL data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
MDGL
Unlock MDGL Supply Chain Data
Verified relationships include:
F-HOFFMANN-LA-ROCHE-LTDF-HOFFMANN-LA-ROCHE-LTDSupplier90%
HOFFMANN-LA-ROCHE-INCHOFFMANN-LA-ROCHE-INCSupplier90%
HTGCHercules Capital, Inc.Customer72%
HTGCHercules Capital, Inc.Customer72%
+26 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →